Oral Orforglipron Bests Oral Semaglutide in Head-to-Head T2D Trial

['Diana Ernst', '.Wp-Block-Co-Authors-Plus-Coauthors.Is-Layout-Flow', 'Class', 'Wp-Block-Co-Authors-Plus', 'Display Inline', '.Wp-Block-Co-Authors-Plus-Avatar', 'Where Img', 'Height Auto Max-Width', 'Vertical-Align Bottom .Wp-Block-Co-Authors-Plus-Coauthors.Is-Layout-Flow .Wp-Block-Co-Authors-Plus-Avatar', 'Vertical-Align Middle .Wp-Block-Co-Authors-Plus-Avatar Is .Alignleft .Alignright'] News Archive - Endocrinology Advisor 2025-09-24 05:47:19

The ACHIEVE-3 trial (ClinicalTrials.gov Identifier: NCT06045221) was a 52-week, randomized, open-label study that included 1698 T2D patients who were randomly assigned 1:1:1:1 to receive orforglipron 12mg, orforglipron 36mg, semaglutide 7mg, or semaglutide 14mg. Superior weight loss was also observed with orforglipron vs semaglutide (change in weight from baseline of 97kg: orforglipron 12mg: -6.6kg [-6.7%]; orforglipron 36mg: -8.9kg [-9.2%]; semaglutide 7mg: -3.6kg [-3.7%]; semaglutide 14mg: -5.0kg [-5.3%]). Change in HbA1c: orforglipron 12mg: -1.7%; orforglipron 36mg: -1.9%; semaglutide 7mg: -1.2%; semaglutide 14mg: -1.5%. Percentage of patients achieving HbA1c of less than 5.7%: orforglipron 12mg: 21.4%; orforglipron 36mg: 31.4%; semaglutide 7mg: 7.4%; semaglutide 14mg: 11.7%. Change in weight: orforglipron 12mg: -6.2kg (-6.1%); orforglipron 36mg: -8.1kg (-8.2%); semaglutide 7mg: -3.8kg (-3.9%); semaglutide 14mg: -5.2kg (-5.3%).